Health Care Down on Deal, Lawsuit Activity -- Health Care Roundup

Dow Jones

Feb 10

Health-care companies fell as fears about health insurers offset deal and lawsuit activity.

Novo Nordisk rose after the Danish maker of obesity drugs Ozempic and Wegovy sued online pharmacy Hims & Hers in an attempt to block any further sales of copycat versions of its weight-loss medications.

Novo rival Eli Lilly rose after it struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash, whose experimental treatments would harness the body's own cells to fight disease.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

February 09, 2026 17:44 ET (22:44 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610664437"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610664437\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610664437?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 06:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610664437","market":"hk","top_or_hot":-1,"title":"Health Care Down on Deal, Lawsuit Activity -- Health Care Roundup","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies fell as fears about health insurers offset deal and lawsuit activity. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> rose after the Danish maker of obesity drugs Ozempic and Wegovy sued online pharmacy Hims &amp; Hers in an attempt to block any further sales of copycat versions of its weight-loss medications. \n</p>\n<p>\n  Novo rival Eli Lilly rose after it struck a deal to buy genetic-medicine biotechnology company Orna <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for up to $2.4 billion in cash, whose experimental treatments would harness the body's own cells to fight disease. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 09, 2026 17:44 ET (22:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health Care Down on Deal, Lawsuit Activity -- Health Care Roundup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth Care Down on Deal, Lawsuit Activity -- Health Care Roundup\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-10 06:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies fell as fears about health insurers offset deal and lawsuit activity. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> rose after the Danish maker of obesity drugs Ozempic and Wegovy sued online pharmacy Hims &amp; Hers in an attempt to block any further sales of copycat versions of its weight-loss medications. \n</p>\n<p>\n  Novo rival Eli Lilly rose after it struck a deal to buy genetic-medicine biotechnology company Orna <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for up to $2.4 billion in cash, whose experimental treatments would harness the body's own cells to fight disease. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 09, 2026 17:44 ET (22:44 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2610664437","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610664437","pubTimestamp":1770677040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Health-care companies fell as fears about health insurers offset deal and lawsuit activity.Novo Nordisk rose after the Danish maker of obesity drugs Ozempic and Wegovy sued online pharmacy Hims & Hers in an attempt to block any further sales of copycat versions of its weight-loss medications.Novo rival Eli Lilly rose after it struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash, whose experimental treatments would harness the body's own cells to fight disease.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","XBI":"SPDR S&P Biotech ETF","LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念","XLV":"健康照护类股ETF-SPDR","BK4581":"高盛持仓"},"translate_title":"医疗保健因交易和诉讼活动而下降——医疗保健综述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":0.6,"XBI":0.6,"XLV":1.5},"content_text":"Health-care companies fell as fears about health insurers offset deal and lawsuit activity. \n\n\nNovo Nordisk rose after the Danish maker of obesity drugs Ozempic and Wegovy sued online pharmacy Hims & Hers in an attempt to block any further sales of copycat versions of its weight-loss medications. \n\n\n  Novo rival Eli Lilly rose after it struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash, whose experimental treatments would harness the body's own cells to fight disease. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n  (END) Dow Jones Newswires\n\n\n  February 09, 2026 17:44 ET (22:44 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}